Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis I.M. Leonie Majoie,

Slides:

Advertisements

Similar presentations

Treatment of generalized lichen nitidus with narrowband ultraviolet B Jae-Hong Park, MD, Yun-Lim Choi, MD, Won-Serk Kim, MD, Dong-Youn Lee, MD, Jun-Mo.

Advertisements

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Lesions referred to dermatology in the Department of Veterans Affairs (VA) health system: A retrospective chart review Katherine R. Grey, BA, Jaime L.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

The protective effect of sunscreens, vitamin E 6% cream, and betamethasone 0.1% cream on solar-simulating radiation-induced erythema and neutrophil influx

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Expression of PD-L1 in mastocytosis

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients Noël Emile Célestin.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Pediatric teledermatology: Observations based on 429 consults

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker Chia-Chi Hsu, MD,

Alopecia areata after dupilumab for atopic dermatitis

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Pilot study of a skin cancer education curriculum for medical students

Pain and nonmelanoma skin cancer in transplant patients

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response Suzanne Tintle, BS, Avner Shemer, MD, Mayte Suárez-Fariñas,

Reply to: “A note on normality”

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Natural killer cell response is a predictor of good outcome in MCPyV+ Merkel cell carcinoma: A case series of 23 patients Valerie Laniosz, MD, PhD, Oluwakemi.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Lip and oral mucosal lesions in 100 renal transplant recipients

Adherence to topical hydrocortisone 17-butyrate 0

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Expression of FcɛRI on dendritic cell subsets in peripheral blood of patients with atopic dermatitis and allergic asthma Inge M.J. Beeren, MSc, Marjolein.

Modulation of Lymphocyte Function In Vivo via Inhibition of Calcineurin or Purine Synthesis in Patients with Atopic Dermatitis Edward F. Knol, Inge M.

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

Epidermal Langerhans Cell Depletion After Artificial Ultraviolet B Irradiation of Human Skin In Vivo: Apoptosis Versus Migration Wendy Kölgen, Hilde.

Stefan Tukaj, PhD, Detlef Zillikens, MD, Michael Kasperkiewicz, MD

Decreased Neutrophil Skin Infiltration After UVB Exposure in Patients with Polymorphous Light Eruption Ines J. Schornagel, Vigfús Sigurdsson, Evert H.J.

Olga Vornicova, MD, Gil Bar-Sela, MD JAAD Case Reports

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Jennifer L. Hundley, MD, Christie L

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Blake R. Zelickson, MD, PhD, Leonard H. Goldberg, MD, Marc K

A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma Alexander.

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis Janneke Landheer,

Eyebrow transplantation: Alternative body sites as a donor source

Recurrence of nevus depigmentosus after an autologous epidermal graft

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Brian B. Johnson, MD, Lisa A. Beck, MD, S. Shahzad Mustafa, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Presentation transcript:

Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis I.M. Leonie Majoie, MD, J. Marja Oldhoff, MD, PhD, Huib van Weelden, MSc, Marloes Laaper-Ertmann, Mente T. Bousema, MD, Vigfus Sigurdsson, MD, PhD, Edward F. Knol, PhD, Carla A.F. Bruijnzeel-Koomen, MD, PhD, Marjolein S. de Bruin-Weller, MD, PhD Journal of the American Academy of Dermatology Volume 60, Issue 1, Pages 77-84 (January 2009) DOI: 10.1016/j.jaad.2008.08.048 Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Trial flow chart. During the treatment period phototherapy was administered 3 times/wk; patients were randomly assigned to receive narrowband ultraviolet (UV) B to one side of the body and medium-dose UVA1 to the other side. LSS, Leicester sign score; VAS, visual analog scale. Journal of the American Academy of Dermatology 2009 60, 77-84DOI: (10.1016/j.jaad.2008.08.048) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Clinical results. Mean reduction in Leicester sign score (LSS) (A) and visual analog scale (VAS) pruritus (B). No significant difference in favor of narrowband (NB) ultraviolet (UV) B. MD, Medium dose; X-axes, time in weeks; Y-axes, mean score. Vertical lines display SD. Journal of the American Academy of Dermatology 2009 60, 77-84DOI: (10.1016/j.jaad.2008.08.048) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Immunohistochemical results (n = 9). Cellular infiltrate before (t = 0) and after (t = 8) phototherapy in patients with atopic dermatitis. Treatment of one body side was with narrowband (NB) ultraviolet (UV) B and other body side with medium-dose (MD) UVA1. AA1, Mast cell; elastase, neutrophil; CD1a, dendritic cell; CD3, T cell; EG2, eosinophil; X-axes, time: 0 = lesional skin, 8 = after 8 weeks of phototherapy; Y-axes, cells/mm2. ∗Significantly different decrease in cells compared with t = 0. No significant differences were observed between NB UVB and MD UVA1 sides. Journal of the American Academy of Dermatology 2009 60, 77-84DOI: (10.1016/j.jaad.2008.08.048) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Immunohistochemical results of forkhead box protein P3 (n = 9). Cellular infiltrate before (t = 0) and after (t = 8) phototherapy in patients with atopic dermatitis. Treatment of one body side was with narrowband (NB) ultraviolet (UV) B and other body side with medium-dose (MD) UVA1. CD3, T cell; FoxP3, positive T cell; X-axes, time: 0 = lesional skin, 8 = after 8 weeks of phototherapy; Y-axes, cells/mm2. ∗Significant decrease in cells compared with t = 0. No significant differences were observed between NB UVB and MD UVA1 sides. Journal of the American Academy of Dermatology 2009 60, 77-84DOI: (10.1016/j.jaad.2008.08.048) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions